New meningitis vaccine trial aims to protect all ages
NCT ID NCT07374510
First seen Jan 29, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This early-stage trial tests a new vaccine designed to protect against several types of meningococcal bacteria that cause meningitis. About 150 healthy volunteers aged 2 to 59 will receive the vaccine or a placebo to check its safety and how well it triggers an immune response. The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGOCOCCAL MENINGITIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.